XTalks

DECEMBER 4, 2024

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Delveinsight

JANUARY 7, 2021

The startup recently raised USD 87 million to propel itself in a competitive market. Ribometrix will apply its proprietary discovery platform to recognize and optimize small molecule compounds, which modulate RNA function by aiming three-dimensional (3D) RNA structures. Terns raises USD 87 Million for NASH drugs.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

MARCH 8, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir. About Ridgeback Biotherapeutics.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

The Pharma Data

JULY 12, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. For further information regarding our clinical trials, please visit [link] or [link]. About Molnupiravir.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

Roots Analysis

JANUARY 28, 2024

Conclusion Owing to the increasing popularity of big data in healthcare domain, there is a huge impact of big data in healthcare market size. Throughout her career, Jayita has contributed to over six syndicate market research reports, covering a wide range of trending domains.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

XTalks

AUGUST 30, 2022

CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. Consider targeting your therapies that fail to be orally bioavailable and brain penetrant. The patients are waiting!

Trials 83

Trials Drug Delivery Drugs Gene 83